Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Spark Therapeutics’ Luxturna nears FDA approval for gene therapy treating inherited blindness In a significant development in gene therapy, Spark Therapeutics’ Luxturna (voretigene neparvovec) is on the verge of receiving… bypharmanewsdailyOctober 15, 2017